15 November
2024
LEI 213800RG7JNX7K8F7525
Life Science REIT plc
("Life Science REIT"
or the "Company")
Purchase of Ordinary Shares by
Investment Adviser
Ironstone Asset Management acquires a
further 532,252 ordinary shares in Life Science REIT
plc
The Board of Life Science REIT (LSE: LABS), the
real estate investment trust focused on UK life science properties,
announces that, in accordance with the terms of the Investment
Advisory Agreement ("IAA") between the Company and Ironstone Asset
Management Limited, (the "Investment Adviser"), it has been
notified that on 13 November 2024, the Investment Adviser has
acquired 532,252 ordinary shares in the share capital of the
company ("Ordinary Shares") at a weighted average price of 42.51
pence per share for a total cost of £227,439.34.
The Ordinary Shares have been purchased
pursuant to the IAA, details of which were disclosed in the
prospectus published by the Company on 14 November 2022.
Following the purchase, the Investment Adviser
has an interest in 1.6 million Ordinary Shares, representing 0.46%
of the Company's issued Ordinary Shares.
Along with this Investment Adviser
purchase, Ironstone Asset Management Limited individuals also own
shares in the Company, taking the total share ownership of the
Investment Adviser and its principals to 5.1 million.
Enquiries:
|
Ironstone Asset Management -
Investment Adviser
|
+44 20 3011 2160
|
|
Simon Farnsworth, Managing
Director
Simon.farnsworth@ironstoneam.com
|
|
|
Joanna Waddingham, Head of Investor
Relations and Corporate Affairs
|
|
|
Joanna.Waddingham@ironstoneam.com
|
|
|
|
|
|
Link Company Matters Limited -
Company Secretary
|
|
|
labs_cosec@linkgroup.co.uk
|
|
|
|
|
|
Panmure Liberum Limited - Joint
Corporate Broker
|
+44 20 3100 2000
|
|
Alex Collins / Tom
Scrivens
|
|
|
|
|
|
Jefferies International Limited -
Joint Corporate Broker
|
+44 20 7029 8000
|
|
Tom Yeadon / Oliver
Nott
|
|
|
G10 Capital Limited -
AIFM
|
+44 20 7397 5450
|
|
Maria Baldwin
|
|
|
FTI Consulting - Financial
PR
|
+44 20 3727 1000
|
|
Dido Laurimore / Richard Gotla /
Oliver Parsons
|
|
|
LifeScienceReit@fticonsulting.com
|
|
Notes to editors
Life Science REIT plc is a
specialist property business focused on the UK's growing life
science sector. The Company's portfolio of assets is located across
the "Golden Triangle" of research and development hubs in Oxford,
Cambridge and London's Knowledge Quarter and its strategic vision
is to become the property provider of choice for life science
companies in the UK.
Life Science REIT is addressing the
acute demand-supply imbalance for laboratory space in the "Golden
Triangle", which is characterised by low vacancy rates and prime
rental increases. The UK life science sector itself is underpinned
by strong structural drivers, including an ageing population and a
supportive regulatory environment as well as the growing
interdependence with technology, which is expanding the life
science spectrum, driving strong demand for laboratory
space.
The Company's diverse portfolio of
assets ranges from a 20-acre science park currently under
development through to fully let buildings, with an important part
of the Company's strategy being the conversion of existing
properties to laboratory space.
The Company's investment policy is
focused on capital growth whilst also providing a growing level of
income.
Life Science REIT trades on the Main
Market of the London Stock Exchange under the ticker
LABS.
Further information is available
at https://lifesciencereit.co.uk.
To sign up for email alerts, please visit https://lifesciencereit.co.uk/investors/.